Form 4: OnKure Therapeutics CFO Sells Shares for Tax Withholding

OnKure Therapeutics, Inc. reports that Chief Financial Officer Jason A. Leverone sold shares to cover tax obligations related to RSU vesting.

Summary

• Jason A. Leverone, Chief Financial Officer of OnKure Therapeutics, Inc., reported a transaction on June 22, 2026.
• The transaction involved the sale of 303 shares of Class A Common Stock.
• These shares were sold automatically to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs).
• The weighted average sale price for these shares was $4.3963, with individual trades ranging from $4.27 to $4.54.
• Following this transaction, Leverone beneficially owns 18,802 shares of Class A Common Stock.
• The filing also notes that Leverone acquired 3,105 shares under the Issuer's 2024 Employee Stock Purchase Plan on May 20, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as the reported stock sale is a routine event for covering tax obligations related to equity compensation and does not indicate a change in the executive's confidence in the company.

Positives

• The sale was an automatic process to cover tax obligations, indicating a standard procedure for equity compensation.
• The company has an RSU Equity Incentive Plan and an Employee Stock Purchase Plan, suggesting mechanisms for employee equity participation.

Negatives

• A portion of the CFO's equity was sold, which could be perceived negatively by investors if not for the tax withholding explanation.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, which is a report of a past transaction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those related to tax withholding upon RSU vesting, are common in the biotechnology and pharmaceutical sectors as companies utilize equity-based compensation to attract and retain talent.

Stakeholder Impact

• Shareholders: The sale is a routine tax event and does not represent a sale based on insider knowledge of company performance, thus having minimal direct impact on share price or ownership structure.

Key Dates

Keywords

OnKure Therapeutics, Form 4, Insider Transaction, Stock Sale, Tax Withholding, RSU Vesting, Chief Financial Officer, Class A Common Stock, Employee Stock Purchase Plan